跳至主要内容
临床试验/NCT01741389
NCT01741389已完成1 期

The Role of Melatonin in the Regulation of Blood Coagulation

University of Oslo1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2012年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
1
主要终点
Circadian variation of hemostatic factors

研究概览

简要总结

The main aim is to examine the influence of daylight and melatonin on the temporal variations of hemostatic factors with key roles in the hemostatic process and its regulation. Particular emphasis will be on exploring the role of melatonin in hemostasis by comparing subjects with tetraplegia with able-bodied control subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Intervention group:
  • A diagnosis of tetraplegia for at least 2 years, and otherwise healthy.
  • Must not use drugs permanently (except anti-spasmolytics).
  • Must be able to swallow tablets.
  • Must give written consent to participate.
  • Control group:
  • Must be healthy.
  • Must not use drugs permanently.
  • Must give written consent to participate.

排除标准

  • Both groups:
  • Those with acute or chronic co-morbidity.
  • Unable to cooperate.
  • Not provided written consent to participate.

研究组 & 干预措施

Sleep only

Placebo Comparator

Placebo given at night to tetraplegic individuals before going to sleep,

干预措施: Melatonin ("Circadin") (Drug)

Melatonin

Active Comparator

Melatonin given at night to tetraplegic individuals before going to sleep.

干预措施: Melatonin ("Circadin") (Drug)

结局指标

主要结局

Circadian variation of hemostatic factors

时间窗: 24 hours

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Per Ole Iversen, MD

Professor

University of Oslo

研究点 (1)

Loading locations...

相似试验